E-GEOD-31437
GSE31437
transcription profiling by array
Homo sapiens
Chemorefractory non-small cell lung cancer gene expression profiles from the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial
·发布 2012年1月1日
·更新 2012年1月11日
131
样本数
131
实验数
1
芯片平台
实验描述
This SuperSeries is composed of the following subset Series: GSE27389: Substitutions in the KRas oncogene determine protein behavior: Implications for signaling and clinical outcome. GSE31428: Final efficacy and biomarker analysis of the sorafenib arm of the BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) trial GSE31852: An EGFR-mutation signature reveals features of the EGFR-dependent phenotype and identifies MACC1 as an EGFR-associated regulator of MET. GSE33072: An epithelial-mesenchymal transition (EMT) gene signature predicts resistance to erlotinib and PI3K pathway inhibitors and identifies Axl as a novel EMT marker in non-small cell lung cancer. Refer to individual Series
芯片平台
A-AFFY-141
Affymetrix GeneChip Human Gene 1.0 ST Array [HuGene-1_0-st-v1]（131 例）
样本属性
8-week disease control (1=yes, 0=no)
0, 1
8_week_disease control_1yes_0no
0, 1, NA
aa change cys vs. other
CYS, Other
aa_change_cys_vs_other
CYS, Other, Other/CYS
base change
G to A, G to T
base_change
A to C, G to A, G to C, G to T, G to T, G to T, GT to TA
biopsy site (grouped): 1
lung
biopsy site (grouped): 3
pleura
biopsy site (grouped): 4
liver
biopsy site (grouped): 5
Adrenal
biopsy site (grouped): 6
Bone/soft tissue component
biopsy site (grouped): 7
Shallow lymph nodes
biopsy site (grouped): 8
Deep lymph nodes
biopsy site (grouped): 9
Dermal/subcutaneous/muscle
codon kras mut
12
concomitant t790m
Yes
date of progression
1/4/2008, 10/20/2008, 2008-02-08, 2008-02-25, 2008-03-31, 2008-04-07, 2008-04-29, 2008-05-05, 2008-06-03, 2008-06-06, 2008-07-16, 2008-08-05, 2008-09-03, 2008-11-01, 2009-03-25, 2009-03-27, 2009-04-05, 2009-06-15, 2009-10-13, 2009-10-22, 2009-12-03, 6/18/2008, 9/25/2008
date_of_progression
., 1-Apr-08, 1-Dec-08, 1-Jun-09, 1-May-08, 1-Oct-08, 11-Nov-08, 14-Sep-09, 15-Jul-09, 16-Jan-09, 16-Jul-09, 17-Nov-09, 18-Aug-08, 18-Jun-09, 19-May-09, 2-Dec-09, 21-Jan-09, 21-Sep-09, 23-Apr-08, 24-Nov-08, 25-Jan-10, 26-Mar-08, 27-Oct-09, 28-Mar-08, 29-Sep-09, 30-Jun-09, 4-Mar-09, 5-Apr-10, 5-Aug-09, 5-Feb-10, 6-Nov-09, 7-Dec-08, 9-Mar-09
disease
non small cell lung cancer
egfr activating mutation
Unknown, unknown, Yes
egfr index
-0.02, -0.03, -0.09, -0.1, -0.12, -0.14, -0.15, -0.18, -0.21, -0.24, -0.25, -0.26, -0.27, -0.28, -0.31, -0.32, -0.33, -0.42, -0.49, -0.5, -0.52, -0.56, -0.59, -0.65, -0.66, -0.67, -0.77, -0.78, -0.85, -0.89, -0.95, -0.96, -1.33, -1.46, -1.6, -1.77, -1.8, -2.1, 0, 0.04, 0.09, 0.11, 0.17, 0.2, 0.21, 0.22, 0.26, 0.27, 0.29, 0.31, 0.32, 0.33, 0.35, 0.37, 0.41, 0.44, 0.5, 0.57, 0.62, 0.63, 0.74, 0.78, 0.81, 0.83, 0.84, 0.86, 0.87, 0.88, 0.89, 0.92, 0.95, 0.97, 0.99, 1.01, 1.03, 1.05, 1.09, 1.1, 1.13, 1.17, 1.2, 1.22, 1.24, 1.25, 1.26, 1.38, 1.42, 1.53, 1.61, 1.64, 1.66, 1.67, 1.77, 1.79, 1.81, 1.97, 2.17, 2.31, 2.38, 2.67
egfr mutation
Mutant, NA, WT
egfr mutation exon
Exon 18, Exon 19, Exon 19/Exon 20, Exon 19/Exon 21, Exon 20, Exon 21, Exon 21/Exon 20
egfr mutation pattern
AAA860ATA, AAC700AGC/GGT721AGT, ACA854ATA, CGG803GGG, del746-750, del746-750/ACG790ATG, del746-750/TGC797TAC, del746-751/ACG790ATG, E20H773R, GAC800TAC, ins774CAC, L858R, L858R/ACG790ATG, loss-16 TC/L858R, TAC813TGC
egfr-iw type
No
gender
female, male
glyc replaced by c, d, v and a
C, D, Other, V
glyc_replaced_by_c_d_v_a
A, C, D, Other, V, V/C
histology-iw revised
adenocarcinoma, Adenosquamous, NSCLC, squamous cell carcinoma
kras mutation
Mutant, NA, WT
kras-iw mutation (yes/no)
No, Yes
kras_mut_codon
10, 12, 13, 61
kras_mut_iw
Yes
kras_mut_type
CAA61CAC, GGC13GAC, GGT12CGT, GGT12GAT, GGT12GCT, GGT12GTA, GGT12GTT, GGT12GTT,GGC13TGC, GGT12TGT, TGG10TAG
markergroup
1, 2, 3, 4
Organism
Homo sapiens
pfsc (1=progressed; 0=not progressed)
0, 1
pfsm (month)
0.4271, 0.5914, 0.8214, 1.0842, 1.117, 1.1499, 1.6099, 1.6756, 1.7413, 1.807, 1.8398, 1.8727, 11.729, 2.4641, 2.5626, 2.7598, 2.7926, 3.5483, 3.614, 3.6468, 3.8768, 4.5339, 4.5667, 5.5195, 6.0123, 6.7351, 8.0493, 8.7392, 9.1663
prior_tx_for_mets
0, 1, 2, 3, 4, 5, 6
progression-free survival status
1, NA
progression-free survival time (months)
0.23, 0.3943, 0.8214, 0.9199, 1.7413, 1.807, 1.8398, 1.8727, 1.9055, 1.9384, 2.037, 2.0698, 2.694, 3.1211, 3.2526, 4.5667, 5.4867, 5.5852, 5.6181, 6.5051, NA
race
Asian, BlackOrAfricanAmerican, White
randomization date
2007-10-23, 2007-12-12, 2008-01-31, 2008-02-01, 2008-02-28, 2008-03-04, 2008-04-11, 2008-05-09, 2008-05-14, 2008-06-04, 2008-08-27, 2009-01-29, 2009-02-27, 2009-03-24, 2009-03-25, 2009-05-05, 2009-08-19, 2009-08-21, 2009-10-08, 4/17/2008, 7/24/2008, 8/25/2008, 9/27/2007
randomization_date
2007-12-12, 2008-01-11, 2008-01-31, 2008-02-06, 2008-02-26, 2008-05-02, 2008-05-15, 2008-05-29, 2008-09-17, 2008-09-23, 2008-10-02, 2008-10-07, 2008-10-30, 2008-12-02, 2008-12-09, 2008-12-22, 2009-01-08, 2009-01-21, 2009-02-04, 2009-04-13, 2009-04-29, 2009-04-30, 2009-05-12, 2009-05-13, 2009-05-14, 2009-05-18, 2009-05-21, 2009-05-27, 2009-06-05, 2009-08-13, 2009-08-26, 2009-10-02, 2009-10-07, 2009-10-14, 2009-10-19, 2009-10-20, 2009-10-28
smoking_status
Former, Never
stage_at_diagnosis
IB, IIB, IIIA, IIIB, IV
transition/transversion
Transition, Transversion
transition_transversion
Transition, Transversion
type kras aa change
ASP, CYS, SER, VAL
type of kras mut
GGT12AGT, GGT12GAT, GGT12GTT, GGT12TGT
type_kras_aa_change
ALA, ARG, ASP, CYS, HIS, STOP, VAL, VAL/CYS
实验信息
登记号
E-GEOD-31437
GEO 编号
GSE31437
实验类型
transcription profiling by array
物种
Homo sapiens
发布日期
2012年1月1日
更新日期
2012年1月11日
提交者
Pierre Saintigny
分析服务
联系地址
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话： 0531-88819269
版权所有 © 2025.Genelibs 济南弘晖生物技术有限公司 鲁ICP备20007159号-2
